Evidence map›Paper›PMID 15277235›Full record

ArticleThe American journal of pathology2004

Lack of integrin alpha1beta1 leads to severe glomerulosclerosis after glomerular injury.

Xiwu Chen, Gilbert Moeckel, Jason D Morrow, Dominic Cosgrove, Raymond C Harris, Agnes B Fogo, Roy Zent, Ambra Pozzi

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in The American journal of pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 93 citations in OpenAlex.

  1. Article
  2. Article
  3. Treatment Approaches for Alport Syndrome.Journal of the American Society of Nephrology : JASN · 2026
    Review
  4. Review
  5. Integrins in the kidney - beyond the matrix.Nature reviews. Nephrology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Cooperative signaling between integrins and growth factor receptors in fibrosis.Journal of molecular medicine (Berlin, Germany) · 2021
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Human genetics of nephrotic syndrome and the quest for precision medicine.Current opinion in nephrology and hypertension · 2016
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiwu ChenDepartment of Medicine, Division of Nephrology and Hypertension, Vanderbilt University, Medical Center North, B3109, 1161 21st Ave., Nashville, TN 37212, USA.
Gilbert Moeckel
Jason D Morrow
Dominic Cosgrove
Raymond C Harris
Agnes B Fogo
Roy Zent
Ambra Pozzi
Vanderbilt University Medical Center · USCancer Genetics (United States) · US

Funding

THE ROLE OF ENDOCANNABINOIDS AND THEIR RECEPTORS IN COLORECTAL CANCERP01CA077839 · NCI · VANDERBILT UNIVERSITY · PI DUBOIS, RAYMOND N. · 1999 to 2016
$17.8M
THE PHARMACOLOGY OF INHIBITORS OF HEME PROTEIN-CATALYZED LIPID PEROXIDATIONP50GM015431 · NIGMS · VANDERBILT UNIVERSITY · PI CAPRIOLI, RICHARD M · 1985 to 2010
$15.0M
ROLE OF SCAVENGER RECEPTORS IN RENAL FIBROSISP50DK044757 · NIDDK · VANDERBILT UNIVERSITY · PI FOGO, AGNES B. · 1992 to 2011
$11.5M
Therapeutic Modulation of Endothelial Cell TetrahydrobiopterinP01GM015431 · NIGMS · VANDERBILT UNIVERSITY · PI MARNETT, LAWRENCE J. · 2011 to 2015
$9.5M
THE ROLE OF CYCLOXGENISE 2 IN PROGRESSIVE NEPHRON DESTRUP50DK039261 · NIDDK · VANDERBILT UNIVERSITY · PI HARRIS, RAYMOND · 1987 to 2007
$6.5M
RESOLUTION OF GLOMERULOSCLEROSISR01DK056942 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FOGO, AGNES B. · 2001 to 2021
$4.9M
BIOCHEMISTRY AND PHARMACOLOGY OF D2/E2-ISOPROSTANESR01DK048831 · NIDDK · VANDERBILT UNIVERSITY · PI YIN, HUIYONG · 1995 to 2008
$2.2M
Control of Tumor Growth by the MMP/Angiostatin PathwayR01CA094849 · NCI · VANDERBILT UNIVERSITY · PI POZZI, AMBRA · 2003 to 2007
$1.9M
Role of Organic Osmolytes in Renal Papillary NecrosisK08DK059975 · NIDDK · VANDERBILT UNIVERSITY · PI MOECKEL, GILBERT WOLFRAM · 2003 to 2007
$616k
NCI NIH HHS CA77839NCI NIH HHS P01 CA077839NCI NIH HHS R01 CA094849NCI NIH HHS R01 CA94849-01NIDDK NIH HHS DK48831NIDDK NIH HHS DK56942NIDDK NIH HHS DK59975NIDDK NIH HHS K08 DK059975NIDDK NIH HHS P50 DK039261NIDDK NIH HHS P50 DK044757NIDDK NIH HHS P50 DK39261-16NIDDK NIH HHS P50 DK44757NIDDK NIH HHS R01 DK048831NIDDK NIH HHS R01 DK056942NIGMS NIH HHS GM15431NIGMS NIH HHS P01 GM015431NIGMS NIH HHS P50 GM015431
6 · The paper itself

Abstract

Severity of fibrosis after injury is determined by the nature of the injury and host genetic susceptibility. Metabolism of collagen, the major component of fibrotic lesions, is, in part, regulated by integrins. Using a model of glomerular injury by adriamycin, which induces reactive oxygen species (ROS) production, we demonstrated that integrin alpha1-null mice develop more severe glomerulosclerosis than wild-type mice. Moreover, primary alpha1-null mesangial cells produce more ROS both at baseline and after adriamycin treatment. Increased ROS synthesis leads to decreased cell proliferation and increased glomerular collagen IV accumulation that is reversed by antioxidants both in vivo and in vitro. Thus, we have identified integrin alpha1beta1 as a modulator of glomerulosclerosis. In addition, we showed a novel pathway where integrin alpha1beta1 modulates ROS production, which in turn controls collagen turnover and ultimately fibrosis. Because integrin alpha1beta1 is expressed in many cell types this may represent a generalized mechanism of controlling matrix accumulation, which has implications for numerous diseases characterized by fibrosis.

Indexed as

AnimalsAntibiotics, AntineoplasticAntioxidantsCell AdhesionCollagen Type IVDoxorubicinGlomerular MesangiumGlomerulosclerosis, Focal SegmentalHomozygoteIntegrin alpha1beta1MaleMiceMice, Inbred BALB CReactive Oxygen SpeciesAntibiotics, AntineoplasticAntioxidantsCollagen Type IVDoxorubicinIntegrin alpha1beta1Reactive Oxygen Species

Identifiers

PMID15277235
PMCPMC1618576
OpenAlexW2158015685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.